PAR •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 08/07/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangePAR
Market Capitalization41.68 mln
Float41.81 mln
Earnings Date09/30/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
14.43
Highly suspicious
Relative Strength
100
/ 100
Top performer
Debt / Equity
-1.10
Negative equity
Pre-Tax Margin
54%
Exceptional margin
Dividend Yield
0.00%
No dividend
Business Description
AB Science is a French pharmaceutical company focused on developing treatments for serious conditions including neurological disorders, inflammatory diseases, and cancer. Its most advanced drug, masitinib, is being studied in late-stage trials for diseases such as ALS, multiple sclerosis, and Alzheimer's, and is already approved in Europe as a veterinary treatment for cancer in dogs. The company also has two earlier-stage drugs in development targeting leukemia and solid tumors. Founded in 2001 and based in Paris, AB Science continues to build a pipeline aimed at some of medicine's most challenging unmet needs.
